EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische Studie

Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial

Chunmei Bai, Yi Zheng, Meili Sun, Jieer Ying, Fuxiang Zhou, Yiyi Yu, Ligang Xing, Yanqiao Zhang, Jinhua Wen, Heshui Wu, Xiuli Yang, Lixin Wan und 27 weitere

European Journal of Cancer · 2025-11 · 230 · 115808

DOI: 10.1016/j.ejca.2025.115808 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2025-11. Verfasst von Chunmei Bai und 38 weiteren Autor:innen. Beteiligte Einrichtung: Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Esophagogastric Junction, Claudins, Stomach Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophagogastric JunctionClaudinsStomach NeoplasmsImmunoconjugatesEsophageal NeoplasmsHumansMaleFemaleMiddle AgedAgedBayes TheoremAdultAged, 80 and over

Stichwörter der Autor:innen

ADCCLDN18.2G/GEJ cancerGastric cancerTecotabart vedotin

Substanzen

ClaudinsImmunoconjugatesCLDN18 protein, human

Autor:innen und Institutionen

  • Peking Union Medical College Hospital, Beijing, China.
  • The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
  • First Affiliated Hospital of Shandong First Medical University, Jinan, China.
  • Zhejiang Cancer Hospital, Hangzhou, China.
  • Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.

Zitieren

APA

Bai, C., Zheng, Y., Sun, M., Ying, J., Zhou, F., Yu, Y., Xing, L., Zhang, Y., Wen, J., Wu, H., Yang, X., Wan, L., Guo, S., Zhao, R., Zhu, Z., Shen, W., Wang, Q., Gu, S., Wu, H., …, & Li, J. (2025). Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial. European Journal of Cancer, 230, 115808. https://doi.org/10.1016/j.ejca.2025.115808

Vancouver

Bai C, Zheng Y, Sun M, Ying J, Zhou F, Yu Y, et al. Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial. European Journal of Cancer. 2025;230:115808. doi:10.1016/j.ejca.2025.115808

BibTeX
@article{Bai2025,
  author = {Bai, Chunmei and Zheng, Yi and Sun, Meili and Ying, Jieer and Zhou, Fuxiang and Yu, Yiyi and Xing, Ligang and Zhang, Yanqiao and Wen, Jinhua and Wu, Heshui and Yang, Xiuli and Wan, Lixin and Guo, Shiwei and Zhao, Rusen and Zhu, Zhizhen and Shen, Wei and Wang, Qi and Gu, Shanzhi and Wu, Hao and Chen, Weichang and Xia, Jin and Zhao, Jun and Dong, Xiaofang and Lou, Wenhui and Jiang, Kuirong and Zhang, Zhiye and Chen, Xiaobing and Fu, Deliang and Chen, Youshan and Wang, Baoqing and Liu, Jiaxin and Ji, Yuan and Yuan, Shijie and Li, Yuan and Gong, Zhihua and Fei, Da and Qin, Xia and Qin, Crystal and Li, Jin},
  title = {Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {230},
  pages = {115808},
  doi = {10.1016/j.ejca.2025.115808}
}
Kostenlos starten →